[
  {
    "date": "2023-12-30",
    "symbol": "SILO",
    "period": "FY",
    "cashandcashequivalentsatcarryingvalue": 3524308,
    "shortterminvestments": 4140880,
    "prepaidexpenseandotherassetscurrent": 15970,
    "assetscurrent": 7681158,
    "prepaidexpensenoncurrent": 64983,
    "assets": 7746141,
    "accountspayableandaccruedliabilitiescurrent": 703488,
    "deferredrevenuecurrent": 72102,
    "liabilitiescurrent": 775590,
    "deferredrevenuenoncurrent": 793680,
    "liabilitiesnoncurrent": 793680,
    "liabilities": 1569270,
    "commonstockvalue": 316,
    "additionalpaidincapitalpreferredstock": 17525714,
    "treasurystockpreferredvalue": 471121,
    "accumulatedothercomprehensiveincomelossnetoftax": -6227,
    "retainedearningsaccumulateddeficit": -10871811,
    "stockholdersequity": 6176871,
    "liabilitiesandstockholdersequity": 7746141,
    "interestreceivablecurrent": 9600,
    "preferredstockparorstatedvaluepershare": 0.0001,
    "preferredstocksharesauthorized": 5000000,
    "commonstockparorstatedvaluepershare": 0.0001,
    "commonstocksharesauthorized": 100000000,
    "commonstocksharesissued": 3159096,
    "commonstocksharesoutstanding": 2906241,
    "treasurystockcommonshares": 252855,
    "revenues": 72102,
    "costofrevenue": 5838,
    "grossprofit": 66264,
    "sharebasedcompensation": 871625,
    "professionalfees": 1726061,
    "researchanddevelopmentexpense": 845092,
    "generalinsuranceexpense": 89007,
    "sellinggeneralandadministrativeexpense": 390071,
    "operatingexpenses": 3921856,
    "operatingincomeloss": -3855592,
    "investmentincomeinterestanddividend": 398530,
    "interestexpense": 4869,
    "penaltyfromearlyterminationofcd": 166034,
    "incomelossfromequitymethodinvestments": -3118,
    "nonoperatingincomeexpense": 224509,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -3631083,
    "incomelossfromcontinuingoperations": -3631083,
    "discontinuedoperationincomelossfromdiscontinuedoperationbeforeincometax": -69600,
    "incomelossfromdiscontinuedoperationsnetoftaxattributabletoreportingentity": -69600,
    "netincomeloss": -3700683,
    "unrealizedgainlossoninvestments": -6227,
    "comprehensiveincomenetoftax": -3706910,
    "incomelossfromcontinuingoperationsperbasicshare": -1.18,
    "incomelossfromdiscontinuedoperationsnetoftaxperbasicshare": -0.02,
    "weightedaveragenumberofsharesoutstandingbasic": 3079874,
    "incomelossfromcontinuingoperationsperdilutedshare": -1.18,
    "incomelossfromdiscontinuedoperationsnetoftaxperdilutedshare": -0.02,
    "weightedaveragenumberofdilutedsharesoutstanding": 3079874,
    "sharesoutstanding": 3159096,
    "adjustmentstoadditionalpaidincapitalsharebasedcompensationstockoptionsrequisiteserviceperiodrecognition": 14125,
    "treasurystockvalueacquiredcostmethod": 471121,
    "treasurystocksharesacquired": 252855,
    "othercomprehensiveincomelossnetoftax": -6227,
    "stockissuedduringperiodsharesreversestocksplits": 299,
    "provisionfordoubtfulaccountsdiscontinuedoperations": 69600,
    "employeebenefitsandsharebasedcompensation": 14125,
    "amortizationofprepaidstockbasedexpense": 90067,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": -35695,
    "increasedecreaseinreceivables": 3590,
    "increasedecreaseinaccountspayableandaccruedliabilities": 339272,
    "increasedecreaseindeferredrevenue": -72102,
    "netcashprovidedbyusedinoperatingactivities": -3224498,
    "paymentsforproceedsfromshortterminvestments": 4147107,
    "netcashprovidedbyusedininvestingactivities": -4147107,
    "paymentsforrepurchaseofotherequity": 471121,
    "netcashprovidedbyusedinfinancingactivities": -471121,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseexcludingexchangerateeffect": -7842726,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": 3524308,
    "interestpaidnet": 4869,
    "changeinaccumulatedothercomprehensivelossandshortterminvestments": 6227,
    "liquiditypolicytextblock": "Liquidity",
    "equityinvestmentsatfairvaluepolicytextblock": "Equity Investments, at Fair Value",
    "prepaidexpensespolicytextblock": "Prepaid Expenses",
    "costofrevenuespolicytextblock": "Cost of Revenues",
    "scheduleofsummarizesactivityinthecompanysshortterminvestmentsandequityinvestmentsatfairvaluetabletextblock": "The following table summarizes activity in theCompany’s short-term investments, at fair value for the periods presented:",
    "scheduleofmilestonepaymentstabletextblock": "On December 31, 2022, prepaid expense and other current assets – current amounted to $5,000 and prepaid expense– non-current amounted to $60,625 as reflected in the consolidated balance sheets.",
    "scheduleofminimumannualroyaltypaymentstabletextblock": "minimumannual royalty payments, as follows:",
    "scheduleofshallpayumbfeestabletextblock": "Pursuant to the July 2021 Sponsored Research Agreement, the Companyshall pay UMB the fees below:",
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 28849,
    "additionsofshortterminvestments": 4147107,
    "disposalgroupincludingdiscontinuedoperationinterestexpense": 69600,
    "disposalgroupincludingdiscontinuedoperationoperatingincomeloss": -69600,
    "notesreceivablenet": 60000,
    "notesreceivablegross": 69600,
    "financingreceivableallowanceforcreditlosses": 69600,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 28849,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 7.28,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P5Y3M21D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingintrinsicvalue": 8610,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 28849,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 7.28,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": "P5Y3M21D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableintrinsicvalue1": 8610,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsnonvestednumber": 1559,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsnonvestedweightedaveragegrantdatefairvalue": 14.05,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsoutstandingweightedaverageremainingcontractualterms": "P2Y3M18D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsnumberofoptionsexercisable": 404580,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsweightedaverageexercisepriceexercisable": 14.05,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsweightedaverageremainingcontractualtermyearsexercisable": "P2Y3M18D",
    "milestonebalancedescription": "Filing of an Investigational New Drug (or any foreign equivalent) for a Licensed Product",
    "milestonepayment": 50000,
    "minimumannualroyaltypaymentsdescription": "Prior to First Commercial Sale",
    "royaltyexpense": 25000,
    "paymentsforfees": 75000,
    "paymentdescription": "Paid upon execution of the July 2021 Sponsored Research Agreement",
    "lesseeoperatingleaseliabilitypaymentsduenexttwelvemonths": 725244,
    "lesseeoperatingleaseliabilitypaymentsdue": 725244,
    "incometaxreconciliationincometaxexpensebenefitatfederalstatutoryincometaxrate": -777143,
    "incometaxreconciliationstateandlocalincometaxes": -240544,
    "incometaxreconciliationotheradjustments": 29510,
    "incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": 988177,
    "deferredtaxassetsoperatinglosscarryforwards": 2538565,
    "deferredtaxassetsvaluationallowance": 2538565,
    "deferredtaxassetsnet": 2538565,
    "accountspayableinterestbearinginterestrate": 0.08,
    "longtermdebtmaturitydate": "2023-10-01",
    "workingcapital": 6905568,
    "cashfdicinsuredamount": 250000,
    "cashspicinsuredamount": 250000,
    "baddebtexpense": 69600,
    "receivablewithimputedinterestfaceamount": 60000,
    "prepaidexpenseandotherassetsnoncurrent": 64983,
    "debtinstrumentfaceamount": 60000,
    "stockissuedduringperiodsharesstocksplits": 105000000,
    "preferredstocksharedesignated": 4280,
    "preferredstockvalue": 1000,
    "convertiblepreferredstocktermsofconversion": "share of Series C Convertiblepreferred stock was convertible, at any time and from time to time after the issuance date, at the option of the holder, into such numberof shares of common stock determined by dividing the Series C Stated Value by the Series C Conversion Price.",
    "preferredstockconvertibleconversionprice": 15,
    "stockissuedduringperiodsharespurchaseofassets": 252855,
    "commonstockpurchasecost": 471121,
    "stockissuedduringperiodsharesemployeebenefitplan": 300000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.0118,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P2Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 1.17,
    "deferredcompensationequity": 14125,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestednumberofshares": 6000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedinperiodfairvalue1": 94915,
    "deferredcompensationarrangementwithindividualcompensationexpense": 94915,
    "concentrationriskpercentage1": 1,
    "officerscompensation": 120000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardsharespurchasedforaward": 16000,
    "derivativeliabilitymeasurementinput": 1.18,
    "otherdeferredcostsnet": 14125,
    "commercialsaleterm": "P10Y",
    "licenseagreementexpire": "P15Y",
    "sublicenseincomereceivablepercentage": 0.25,
    "duetorelatedpartiecurrent": 25000,
    "prepaidexpenseothernoncurrent": 55625,
    "salesoflicensedproductspercentage": 0.03,
    "salescommissionsandfees": 50000000,
    "proceedsfromlicensefeesreceived": 838,
    "nonrefundablecashpayment": 500000,
    "netsalepercentage": 0.02,
    "licensorshare": 500,
    "aggregateofconvertedshares": 625000,
    "revenueterm": "P15Y",
    "deferredrevenue": 1031250,
    "cash": 500000,
    "securitiesreceived": 531250,
    "deferredrevenuerevenuerecognized1": 68750,
    "considerationfeepayablepercentage": 1.1,
    "upfrontlicensefees": 50000,
    "firstcommercialsale": "P10Y",
    "agreementshallexpire": "P15Y",
    "othernotespayable": 81474,
    "sponsoredstudyagreement": 40737,
    "repaymentsofotherdebt": 330825,
    "revenueremainingperformanceobligation": 60570,
    "otherresearchanddevelopmentexpense": 71427,
    "accountspayableandotheraccruedliabilitiescurrent": 92095,
    "sponsoredresearchagreementdescription": "the Company shall pay a total of $1,436,082 to Columbia Universityfor the support of the research according to the payment schedule as follows: (i) 30% at signing, (ii) 30% at four and half months afterthe start of the project, (iii) 30% at nine months after the start of the project and, (iv)10% at completion of the project.",
    "accountspayablecurrent": 143607,
    "researchprojectestimatepercentage": 0.9,
    "proceedsfromfeesreceived": 177903,
    "definedcontributionplancostrecognized": 225000,
    "jointventureinterestrate": 0.51,
    "sharebasedcompensationarrangementbysharebasedpaymentawardexpirationperiod": "P24M",
    "operatinglosscarryforwards": 9231000,
    "financingreceivablebeforeallowanceforcreditlosstototalpercent": 1,
    "documenttype": "10-K",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentfinstmterrorcorrectionflag": "false",
    "entityinteractivedatacurrent": "Yes",
    "icfrauditorattestationflag": "false",
    "amendmentflag": "false",
    "documentperiodenddate": "2023-12-31",
    "documentfiscalyearfocus": 2023,
    "documentfiscalperiodfocus": "FY",
    "entityregistrantname": "SILO PHARMA, INC",
    "entitycentralindexkey": 1514183,
    "entityfilenumber": "001-41512",
    "entitytaxidentificationnumber": "27-3046338",
    "entityincorporationstatecountrycode": "NV",
    "currentfiscalyearenddate": "--12-31",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityshellcompany": "false",
    "entityfilercategory": "Non-accelerated Filer",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "false",
    "entityaddressaddressline1": "677 N. Washington Boulevard",
    "entityaddresscityortown": "Sarasota",
    "entityaddressstateorprovince": "FL",
    "entityaddresspostalzipcode": 34236,
    "cityareacode": "(718)",
    "localphonenumber": "400-9031",
    "security12btitle": "Common Stock, $0.0001 par value per share",
    "tradingsymbol": "SILO",
    "securityexchangename": "NASDAQ",
    "auditorname": "SALBERG & COMPANY, P.A.",
    "auditorfirmid": 106,
    "auditorlocation": "Boca Raton, Florida"
  },
  {
    "date": "2022-12-30",
    "symbol": "SILO",
    "period": "FY",
    "cashandcashequivalentsatcarryingvalue": 11367034,
    "equityinvestmentsatcost": 3118,
    "prepaidexpenseandotherassetscurrent": 181710,
    "accountsandotherreceivablesnetcurrent": 66010,
    "assetscurrent": 11572056,
    "prepaidexpensenoncurrent": 70821,
    "assets": 11642877,
    "loanspayablecurrent": 364216,
    "deferredrevenuecurrent": 72102,
    "liabilitiescurrent": 436318,
    "deferredrevenuenoncurrent": 865782,
    "liabilitiesnoncurrent": 865782,
    "liabilities": 1302100,
    "commonstockvalue": 316,
    "additionalpaidincapital": 17511589,
    "retainedearningsaccumulateddeficit": -7171128,
    "stockholdersequity": -7171128,
    "liabilitiesandstockholdersequity": 11642877,
    "interestreceivablecurrent": 6010,
    "preferredstockparorstatedvaluepershare": 0.0001,
    "preferredstocksharesauthorized": 4280,
    "preferredstockredemptionpricepershare": 100,
    "preferredstockliquidationpreference": 1000,
    "commonstockparorstatedvaluepershare": 0.0001,
    "commonstocksharesauthorized": 500000000,
    "commonstocksharesissued": 3158797,
    "commonstocksharesoutstanding": 3158797,
    "licensefees": 72102,
    "costofrevenue": 5838,
    "grossprofit": 66264,
    "sharebasedcompensation": 577651,
    "professionalfees": 1496687,
    "researchanddevelopmentexpense": 241288,
    "generalinsuranceexpense": 125889,
    "provisionfordoubtfulaccounts": -20000,
    "sellinggeneralandadministrativeexpense": 227259,
    "operatingexpenses": 3693920,
    "operatingincomeloss": -3627656,
    "interestanddividendincomeoperating": 72637,
    "otherincome": 85733,
    "interestexpense": 2199,
    "gainlossoninvestments": -104700,
    "unrealizedgainlossonequityinvestments": -331203,
    "nonoperatingincomeexpense": -279732,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -3907388,
    "incomelossfromcontinuingoperations": -3907388,
    "discontinuedoperationincomelossfromdiscontinuedoperationbeforeincometax": -1163,
    "incomelossfromdiscontinuedoperationsnetoftaxattributabletoreportingentity": -1163,
    "netincomeloss": -3908551,
    "netincomelossavailabletocommonstockholdersdiluted": -3908551,
    "incomelossfromcontinuingoperationsperbasicshare": -1.71,
    "incomelossfromcontinuingoperationsperdilutedshare": -1.71,
    "weightedaveragenumberofsharesoutstandingbasic": 2284240,
    "weightedaveragenumberofdilutedsharesoutstanding": 2284240,
    "sharesoutstanding": 3158797,
    "stockissuedduringperiodvaluenewissues": 4940948,
    "saleofstocknumberofsharesissuedintransaction": 1150000,
    "amortizationofprepaidstockbasedcompensation": 111014,
    "stockissuedduringperiodvaluecommonsharesissuedforprofessionalfees": 135100,
    "stockissuedduringperiodsharescommonsharesissuedforprofessionalfeesinshares": 20000,
    "commonstockissuedforconversionofseriescpreferredstock": -2,
    "commonstockissuedforconversionofredeemableseriesapreferredstockinshares": 15167,
    "stockissuedduringperiodsharesother": 891,
    "employeebenefitsandsharebasedcompensation": 156047,
    "incomelossfromequitymethodinvestments": -104700,
    "unrealizedgainlossoninvestments": -331203,
    "equitysharesearnedforservices": -85733,
    "increasedecreaseinprepaidexpense": -55335,
    "increasedecreaseinreceivables": 4800,
    "increasedecreaseinaccountspayableandaccruedliabilities": -53721,
    "increasedecreaseindeferredrevenue": -72102,
    "netcashprovidedbyusedinoperatingactivities": -3497622,
    "proceedsfromsaleofequitymethodinvestments": 66707,
    "collectiononnotereceivable": 20000,
    "netcashprovidedbyusedininvestingactivities": 86707,
    "proceedsfromissuanceofcommonstock": 4940948,
    "netcashprovidedbyusedinfinancingactivities": 4940948,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseexcludingexchangerateeffect": 1530033,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": 11367034,
    "interestpaidnet": 2199,
    "incometaxespaidnet": 25159,
    "commonstockissuedforfutureservices": 135100,
    "liquiditypolicytextblock": "Liquidity ",
    "equityinvestmentsatfairvaluepolicytextblock": "Equity Investments, at Fair Value ",
    "equityinvestmentsatcostpolicytextblock": "Equity Investments, at Cost ",
    "costofrevenuespolicytextblock": "Cost of Revenues ",
    "scheduleofearningspershareantidilutivebasicanddilutedtabletextblock": "            December 31, 2022      December 31, 2021       Series C convertible preferred stock      -       15,133       Stock options      28,849       6,000       Warrants      404,580       347,080              433,429       368,213    ",
    "scheduleofactivityinthecompanysequityinvestmentsatfairvaluetabletextblock": "            December 31, 2022      December 31, 2021       Balance, beginning of year     $419,995      $—       Additions      85,733       531,250       Sales at original cost      (171,407)      (359,843)      Unrealized (loss) gain      (331,203)      248,588       Balance, end of year     $3,118      $419,995    ",
    "scheduleofumbminimumroyaltypayments": "      Years         Minimum        Annual     Royalty           Prior to First Commercial Sale         $    N/A           Year of First Commercial Sale         $    N/A           First calendar year following the First Commercial Sale         $    25,000           Second calendar year following the First Commercial Sale         $    25,000           Third calendar year following the First Commercial Sale         $    100,000        ",
    "scheduleofshallpayumb": "                Payment                     1         $    92,095              Upon execution of the July 2021 Sponsored Research Agreement      2         $    92,095              Six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement      3         $    92,095              Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement   ",
    "scheduleoffutureamountsdueundersponsoredstudyandresearchagreementstabletextblock": "      Year ended December 31,     Amount       2023     $898,967       Total     $898,967    ",
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 433429,
    "netincomelossfromcontinuingoperationsavailabletocommonshareholdersbasic": -3907388,
    "incomelossfromdiscontinuedoperationsnetoftax": -1163,
    "netincomelossavailabletocommonstockholdersbasic": -3908551,
    "weightedaveragenumberofsharescommonstocksubjecttorepurchaseorcancellation": 2284447,
    "netincomelossfromcontinuingoperationsavailabletocommonshareholdersdiluted": -3907388,
    "incomelossfromcontinuingoperationsincludingportionattributabletononcontrollinginterest": -3907388,
    "netincomelossfromdiscontinuedoperationsavailabletocommonshareholdersdiluted": -3908551,
    "weightedaveragebasicsharesoutstandingproforma": 2284240,
    "equityinvestmentsatfairvalue": 3118,
    "equitymethodinvestments": 3118,
    "additionsofequitysecurities": 85733,
    "proceedsfromsaleandmaturityofmarketablesecurities": 171407,
    "marketablesecuritiesunrealizedgainloss": -331203,
    "disposalgroupincludingdiscontinuedoperationcostsofgoodssold": 1079,
    "disposalgroupincludingdiscontinuedoperationgrossprofitloss": -1079,
    "otheroperatingincomeexpensenet": 84,
    "discontinuedoperationtaxeffectofdiscontinuedoperation": -1163,
    "notesreceivablegross": 60000,
    "otherreceivablesnetcurrent": 60000,
    "lessnotesreceivablenetcurrentportion": -60000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 28849,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 7.28,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingintrinsicvalue": 20130,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 16000,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsothershareincreasedecreaseinperiodweightedaverageexerciseprice": 10,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm": 7.28,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 23849,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 14.05,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeexercisableoptionsweightedaverageremainingcontractualterm2": 6.31,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableintrinsicvalue1": 20130,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsnonvestednumber": 404580,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsnonvestedweightedaveragegrantdatefairvalue": 14.05,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsgranted": 57500,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingperiodincreasedecreaseweightedaverageexerciseprice": 6.25,
    "sharebasedpaymentweightedaverageremainingcontractualtermyearsgranted": 5,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualtermyears": 3.3,
    "sharebasedcomponsationnumberofwarrantsexercisableindollars": 404580,
    "sharebasedcomposationweightedaverageremainingcontractualtermyearsexercisable": 3.3,
    "incometaxreconciliationincometaxexpensebenefitatfederalstatutoryincometaxrate": -820796,
    "incometaxreconciliationstateandlocalincometaxes": -254056,
    "incometaxreconciliationotheradjustments": 133994,
    "incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": 940858,
    "deferredtaxassetsoperatinglosscarryforwards": 1550388,
    "deferredtaxassetsvaluationallowance": 1550388,
    "deferredtaxassetsnet": 1550388,
    "milestone": "Achievement of First Commercial Sale of Licensed Product",
    "milestonepayment": 1000000,
    "yearsdescription": "Third calendar year following the First Commercial Sale",
    "minimumannualroyalty": 100000,
    "sponsoredpayment": 92095,
    "paymentdescription": "Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement",
    "operatingleasesfutureminimumpaymentdueintwoyears": 898967,
    "operatingleasesfutureminimumpaymentdue": 898967,
    "netincomelossattributabletononcontrollinginterest": 3908551,
    "netcashprovidedbyusedincontinuingoperations": 3497622,
    "retainedearningsunappropriated": 7171128,
    "workingcapital": 11135738,
    "cashfdicinsuredamount": 250000,
    "cashspicinsuredamount": 250000,
    "fdicindemnificationassetcashpaymentsreceived": 10868000,
    "prepaidexpenseandotherassets": 135894,
    "prepaidexpenseandotherassetsnoncurrent": 70821,
    "netrealizedgainlossonequityinvestments": 104700,
    "sharesreceivedofcommonstock": 1559,
    "interestratederivativeinstrumentsnotdesignatedashedginginstrumentsatfairvaluenet": 85733,
    "netrealizedgainlossonequityinvestmentspershare": 55,
    "gainonsaleofinvestments": 171407,
    "grossproceeds": 66707,
    "investmentownedbalanceprincipalamount": 60000,
    "interestreceivable": 6010,
    "financingreceivablesbeforeallowanceforcreditlossaverageamountoutstanding": 66010,
    "derivativefixedinterestrate": 0.1,
    "debtinstrumentinterestrateincreasedecrease": 0.18,
    "assetsneededforimmediatesettlementaggregatefairvalue": 20000,
    "baddebtrecoveryexpense": 20000,
    "remainscollectiblesettlementagreementamountreserved": 35500,
    "debtinstrumentperiodicpaymentprincipal": 60000,
    "paymentstoacquirereceivables": 66010,
    "excessstocksharesauthorized": 505000000,
    "preferredstockstatedvalue": 1000,
    "debtinstrumentconvertibleconversionprice1": 15,
    "convertiblepreferredstocktermsofconversion": "A holder of Series C Convertible preferred stock may not convert any portion of the Series C Convertible preferred stock to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% (or, upon election by a holder prior to issuance, 9.99%) of the outstanding shares of the Company’s common stock after conversion, which beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99%.",
    "warrantsterm": "five years",
    "classofwarrantorrightexercisepriceofwarrantsorrights1": 15,
    "investorinvestedamountpercentage": 0.5,
    "constructioncontractorliquiditycharacteristic": "If the Company fails to file the Registration Statement or have it declared effective bythe dates set forth above, amongst other things, the Company will be obligated to pay the investors damages in the amount of 1% of theirsubscription amount, per month, until such events are satisfied.",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.0118,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": 2,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 1.17,
    "aggregategrantdatefairvalueofplacementagentwarrants": 1106000,
    "accruedprofessionalfeescurrentandnoncurrent": 45033,
    "increasedecreaseinprepaidexpensesother": 90067,
    "deferredcompensationequity": 80790,
    "otherdeferredcompensationarrangementsliabilityclassifiednoncurrent": 14125,
    "sharebasedcompensationarrangementbysharebasedpaymentawardsharespurchasedforaward": 16000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedinperiodfairvalue1": 94915,
    "deferredcompensationarrangementwithindividualcompensationexpense": 94915,
    "allocatedsharebasedcompensationexpense": 83728,
    "operatinglosscarryforwards": 5638000,
    "financingreceivablebeforeallowanceforcreditlosstototalpercent": 1,
    "deferredtaxassetsother": 940858,
    "concentrationsriskpercentage1": 1,
    "supplementalunemploymentbenefitssalarycontinuation": 180000,
    "otherdeferredcostsnet": 80790,
    "deferredcompensationarrangementwithindividualallocatedsharebasedcompensationexpense": 14125,
    "licensefee": 828,
    "paymentsforfees": 75000,
    "commercialsaleterm": 10,
    "licenseagreementexpire": 15,
    "sublicenseincomereceivablepercentage": 0.15,
    "duetorelatedpartiecurrent": 25000,
    "prepaidexpenseothernoncurrent": 10196,
    "salesoflicensedproductspercentage": 0.05,
    "salescommissionsandfees": 50000000,
    "otherprepaidexpensecurrent": 838,
    "nonrefundablecashpayment": 500000,
    "netsalepercentage": 0.02,
    "licensorshare": 500,
    "aggregateofconvertedshares": 625000,
    "revenueterm": 15,
    "deferredrevenue": 1031250,
    "cashreceived": 500000,
    "securitiesreceived": 531250,
    "deferredrevenuerevenuerecognized1": 68750,
    "recognitionofdeferredrevenue": 3352,
    "deferredrevenuelongtermportionamounted": 40782,
    "considerationfeepayablepercentage": 1.1,
    "upfrontlicensefees": 1900000,
    "firstcommercialsale": 10,
    "agreementshallexpire": 15,
    "recognizedrevenues": 3352,
    "othernotespayable": 40737,
    "sponsoredstudyagreement": 40737,
    "otherresearchanddevelopmentexpense": 33252,
    "researchanddevelopmentfees": 10857,
    "accountspayablerelatedpartiecurrent": 92095,
    "accruedliabilitiescurrent": 12080,
    "effectiveincometaxratereconciliationtaxcreditsresearch": 0.7000000000000001,
    "paymentofuniversity": 5000,
    "accruedprofessionalfeescurrent": 25000,
    "entityregistrantname": "SILO PHARMA, INC",
    "tradingsymbol": "SILO",
    "documenttype": "10-K",
    "currentfiscalyearenddate": "December 31",
    "amendmentflag": "false",
    "entitycentralindexkey": 1514183,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "December 31, 2022",
    "documentfiscalyearfocus": 2022,
    "documentfiscalperiodfocus": "FY",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "true",
    "icfrauditorattestationflag": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "entityfilenumber": "001-41512",
    "entityincorporationstatecountrycode": "Delaware",
    "entitytaxidentificationnumber": "27-3046338",
    "entityaddressaddressline1": "560 Sylvan Avenue",
    "entityaddressaddressline2": "Suite 3160",
    "entityaddresscityortown": "Englewood Cliffs",
    "entityaddressstateorprovince": "New Jersey",
    "entityaddresspostalzipcode": 7632,
    "cityareacode": "(718)",
    "localphonenumber": "400-9031",
    "security12btitle": "Common Stock, $0.0001 par value per share",
    "securityexchangename": "Nasdaq",
    "entityinteractivedatacurrent": "Yes",
    "auditorfirmid": 106,
    "auditorname": "Salberg & Company,P.A.",
    "auditorlocation": "Boca Raton, Florida"
  },
  {
    "date": "2021-12-30",
    "symbol": "SILO",
    "period": "FY",
    "cashandcashequivalentsatcarryingvalue": 9837001,
    "equityinvestmentsatcost": 419995,
    "prepaidexpenseandotherassetscurrent": 7715,
    "assetscurrent": 10402320,
    "otherassetsnoncurrent": 61210,
    "prepaidexpensenoncurrent": 26659,
    "assets": 10490189,
    "accountspayableandaccruedliabilitiescurrent": 417937,
    "duetorelatedpartiescurrent": 72102,
    "liabilitiescurrent": 490039,
    "deferredrevenuenoncurrent": 937884,
    "liabilitiesnoncurrent": 937884,
    "liabilities": 1427923,
    "commonstockvalue": 9864,
    "additionalpaidincapital": 12314979,
    "retainedearningsaccumulateddeficit": -3262577,
    "stockholdersequity": -3262577,
    "liabilitiesandstockholdersequity": 10490189,
    "interestreceivablenoncurrent": 1210,
    "preferredstockparorstatedvaluepershare": 0.0001,
    "preferredstocksharesauthorized": 4280,
    "preferredstocksharesissued": 227,
    "preferredstocksharesoutstanding": 227,
    "preferredstockredemptionpricepershare": 1000,
    "commonstockparorstatedvaluepershare": 0.0001,
    "commonstocksharesauthorized": 500000000,
    "commonstocksharesissued": 98636970,
    "commonstocksharesoutstanding": 98636970,
    "licensefees": 71264,
    "costofrevenue": 5004,
    "grossprofit": 66260,
    "sharebasedcompensation": 395123,
    "professionalfees": 1598367,
    "researchanddevelopmentexpense": 693910,
    "generalinsuranceexpense": 108750,
    "baddebtrecoveryexpense": -148500,
    "sellinggeneralandadministrativeexpense": 162953,
    "operatingexpenses": 2810603,
    "operatingincomeloss": -2744343,
    "interestincomeother": 1210,
    "gainslossesonrecoursedebt": 19082,
    "interestexpensedebt": 3036,
    "gainlossoninvestments": 6660483,
    "unrealizedgainlossonequityinvestments": 248588,
    "nonoperatingincomeexpense": 6926327,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": 4181984,
    "incometaxexpensebenefit": 24876,
    "incomelossfromcontinuingoperations": 4157108,
    "discontinuedoperationgainlossondisposalofdiscontinuedoperationnetoftax": 1553,
    "discontinuedoperationincomelossfromdiscontinuedoperationbeforeincometax": -254920,
    "incomelossfromdiscontinuedoperationsnetoftaxattributabletoreportingentity": -253367,
    "profitloss": 3903741,
    "preferredstockdividendsincomestatementimpact": 1403997,
    "netincomelossavailabletocommonstockholdersdiluted": 2499744,
    "earningspersharebasic": 0.04,
    "earningspersharediluted": 0.04,
    "weightedaveragenumberofsharesoutstandingbasic": 94865761,
    "weightedaveragenumberofdilutedsharesoutstanding": 95922218,
    "sharesoutstanding": 98636970,
    "stockissuedduringperiodvalueother": 3794102,
    "stockissuedduringperiodsharesother": 4276,
    "stockandwarrantsissuedduringperiodvaluepreferredstockandwarrants": -1403997,
    "stockissuedduringperiodvalueissuedforservices": 83728,
    "issuanceofcommonstockforconversionofpreferredstock": -1350,
    "issuanceofcommonsharesforconversionofpreferredstockinshares": 13495014,
    "netincomeloss": 3903741,
    "provisionfordoubtfulaccounts": -148500,
    "employeebenefitsandsharebasedcompensation": 83728,
    "amortizationofprepaidstockbasedexpense": 107970,
    "incomelossfromequitymethodinvestments": 6660483,
    "unrealizedgainlossoninvestments": 248588,
    "gainslossesonrestructuringofdebt": 19082,
    "gainlossondispositionofassets": 1553,
    "increasedecreaseinprepaidexpense": 38862,
    "increasedecreaseinassetsofdiscontinuedoperation": -24963,
    "increasedecreaseinreceivables": 1210,
    "increasedecreaseinaccountspayableandaccruedliabilities": 291050,
    "increasedecreaseindeferredrevenue": 478736,
    "netcashprovidedbyusedinoperatingactivities": -2278016,
    "proceedsfromsaleofequitymethodinvestments": 7020526,
    "proceedsfromcollectionofnotesreceivable": 7500,
    "collectiononnotereceivable": 164500,
    "netcashprovidedbyusedininvestingactivities": 7192526,
    "proceedsfromissuanceofpreferredstockandpreferencestock": 3794102,
    "advancefromarelatedparty": 2366,
    "proceedsfromrepaymentsofotherlongtermdebt": -2366,
    "netcashprovidedbyusedinfinancingactivities": 3794102,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseexcludingexchangerateeffect": 8708612,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": 9837001,
    "increaseinequityinvestmentsrecordedasdeferredrevenuepursuanttoapatentlicenseagree": 531250,
    "notereceivableissuedinconnectionwithassetpurchaseagreement": 60000,
    "liquiditypolicytextblock": "Liquidity ",
    "equityinvestmentsatfairvaluepolicytextblock": "Equity Investments, at Fair Value ",
    "equityinvestmentsatcostpolicytextblock": "Equity Investments, at Cost ",
    "costofrevenuespolicytextblock": "Cost of Revenues ",
    "scheduleofearningspershareantidilutivebasicanddilutedtabletextblock": "            December 31, 2021      December 31, 2020       Series C convertible preferred stock      756,667       —       Stock options      300,000       300,000       Warrants      17,353,987       —              18,410,654       300,000    ",
    "scheduleofactivityinthecompanysequityinvestmentsatfairvaluetabletextblock": "            December 31, 2021      December 31, 2020       Balance, beginning of the year     $—      $   —       Additions      531,250       —       Sales      (359,843)      —       Unrealized gain      248,588       —       Balance, end of the year     $419,995      $—    ",
    "scheduleofumbminimumroyaltypayments": "      Years     Minimum Annual Royalty       Prior to First Commercial Sale     $N/A       Year of First Commercial Sale     $N/A       First calendar year following the First Commercial Sale     $25,000       Second calendar year following the First Commercial Sale     $25,000       Third calendar year following the First Commercial Sale     $100,000    ",
    "scheduleofshallpayumb": "      Payment                1         $    92,095              Upon execution of the July 2021 Sponsored Research Agreement      2         $    92,095              Six months after the start of project work as outlined in the July 2021 Sponsored Research Agreement      3         $    92,095              Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement   ",
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 18410654,
    "incomelossfromcontinuingoperation": 4157108,
    "incomelossfromdiscontinuedoperations": -253367,
    "netincomelossavailabletocommonstockholdersbasic": 3903741,
    "incomelossfromcontinuingoperationsperbasicshare": 0.04,
    "interestincomeexpensenet": -3036,
    "numeratorforlossfromcontinuingoperationspercommonsharediluted": 4154072,
    "numeratorforlossfromdiscontinuingoperationspercommonsharediluted": -253367,
    "netincomelossallocatedtogeneralpartners": 3900705,
    "incrementalcommonsharesattributabletosharebasedpaymentarrangements": 299790,
    "auctionmarketpreferredsecuritiessharesoutstanding": 756667,
    "weightedaveragenumberdilutedsharesoutstandingadjustment": 95922218,
    "incomelossfromcontinuingoperationsperdilutedshare": 0.04,
    "equityinvestmentsatfairvalue": 419995,
    "equitymethodinvestments": 419995,
    "additionsofequitysecurities": 531250,
    "proceedsfromsaleandmaturityofmarketablesecurities": 359843,
    "marketablesecuritiesunrealizedgainloss": 248588,
    "proceedsfromsaleofproductiveassets": 119405,
    "disposalgroupincludingdiscontinuedoperationcostsofgoodssold": 103824,
    "disposalgroupincludingdiscontinuedoperationgrossprofitloss": 15581,
    "othernonoperatingincomeexpense": 270501,
    "gainfromsaleofnfidbusiness": 1533,
    "incomelossfromdiscontinuedoperationsnetoftax": -253367,
    "notesreceivablegross": 220000,
    "additionalnotesreceivablein2021": 60000,
    "collectionsonnotesreceivables": 148500,
    "financingreceivableallowanceforcreditlosses": 71500,
    "otherreceivablesnetcurrent": 60000,
    "notesreceivablenet": 60000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 300000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprices": 0.0001,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingintrinsicvalue": 42870,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": 4.12,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 300000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 0.31,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeexercisableoptionsweightedaverageremainingcontractualterm2": 2.5,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableintrinsicvalue1": 42870,
    "numberofwarrant": 17353987,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 0.31,
    "sharebasedcomponsationnumberofwarrantsexercisableindollars": 17353987,
    "sharebasedcomposationweightedaverageremainingcontractualtermyearsexercisable": 4.12,
    "sharebasedcomponsationnumberofwarrantsgranted": 17353987,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 0.31,
    "sharebasedcomponsationweightedaverageremainingcontractualtermyearsgranted": 4.12,
    "incometaxreconciliationincometaxexpensebenefitatfederalstatutoryincometaxrate": 819786,
    "incometaxreconciliationstateandlocalincometaxes": 253743,
    "availableforsalesequitysecuritiesgrossunrealizedgain": -20893,
    "incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": -1027760,
    "deferredtaxassetsoperatinglosscarryforwards": 1647335,
    "deferredtaxassetscapitallosscarryforward": -1707701,
    "deferredtaxassetgross": -60366,
    "deferredtaxassetsvaluationallowances": 35490,
    "milestone": "Achievement of First Commercial Sale of Licensed Product",
    "milestonepayment": 1000000,
    "umbyeardescription": "Third calendar year following the First Commercial Sale",
    "umbpayment": 100000,
    "payment": 43885,
    "paymentdescription": "Upon completion of the project work as outlined in the July 2021 Sponsored Research Agreement",
    "sponsoredpayment": 92095,
    "netincomelossattributabletononcontrollinginterest": 3903741,
    "netcashprovidedbyusedincontinuingoperations": 2278016,
    "saleofstockconsiderationreceivedontransaction": 7020526,
    "capitalunits": 9912281,
    "sharesissued": 12,
    "cashfdicinsuredamount": 250000,
    "cashspicinsuredamount": 250000,
    "fdicindemnificationassetcashpaymentsreceived": 9100000,
    "prepaidexpenseandotherassets": 145324,
    "inventorygross": 26659,
    "deferredincometaxexpensebenefit": 24876,
    "otherresearchanddevelopmentexpense": 693910,
    "fairvaluenetderivativeassetliabilitymeasuredonrecurringbasisunobservableinputsreconciliationgainlossincludedinearnings": 3363,
    "investmentownedatcost": 200,
    "deferredsalescommission": 578880,
    "principalbalance": 60000,
    "accruedinterestreceivable": 1210,
    "totaloutstandingbalancereceivable": 61210,
    "notesandloansreceivablenetcurrent": 50000,
    "allowanceforloanandleaselossrecoveryofbaddebts": 148500,
    "collectedsettlementagreement": 148500,
    "remainscollectiblesettlementagreement": 47500,
    "notereceivablenoncurrentamount": 60000,
    "debtinstrumentincreasesaccruedinterest": 1210,
    "paymentstoacquirereceivables": 61210,
    "debtinstrumentfaceamount": 18900,
    "debtinstrumentincreaseaccruedinterest": 182,
    "othernotespayable": 19082,
    "interestexpense": 54,
    "commonstockissuedforconversionofredeemableseriespreferredstockshares": 1000,
    "debtinstrumentconvertibleconversionprice1": 0.3,
    "preferredstockoutstandingdescription": "Aholder of Series C Convertible Preferred Stock may not convert any portion of the Series C Convertible Preferred Stock to the extentthat the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% (or, upon electionby a holder prior to issuance, 9.99%) of the outstanding shares of the Company’s common stock after conversion, which beneficialownership limitation may be increased by the holder up to, but not exceeding, 9.99%.",
    "warrantsterm": "five years",
    "classofwarrantorrightexercisepriceofwarrantsorrights1": 0.3,
    "warrantsperiod": 180,
    "investorinvestedamountpercentage": 0.5,
    "obligationpercentage": 0.01,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.005,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": 5,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 1.69,
    "aggregategrantdatefairvalueofplacementagentwarrants": 1106000,
    "preferredstockshareoutstanding": 227,
    "investorinvestedamount": 100000,
    "subsequentfinancingpercentage": 0.5,
    "constructioncontractorliquiditycharacteristic": "the Company is obligated to pay the investors liquidateddamages in the amount of 1% of their subscription amount, per month, until such events are satisfied, subject to a cap of 6%.",
    "commonstockservicedescription": "The warrants were valued on the grantdate at approximately $0.33 per warrant for a total of $83,728 using a Black-Scholes option pricing model with the following assumptions:stock price of $0.35 per share (based on the quoted trading price on the date of grant), volatility of 169%, expected term of five year,and a risk-free interest rate of 0.46%.",
    "stockissuedduringperiodvaluesharebasedcompensationgross": 83728,
    "venturecapitalgainslossesnet": 6660483,
    "netcapitallosscarryforward": 450663,
    "gainlossonsaleofcapitalleasenet": 6209820,
    "aggregateestimatednetoperatingloss": 5990308,
    "descriptionofincometaxdescription": "The net loss carryforward up until 2017 in the amount of $470,204, will expire in 2037. Net loss carryforwards in the amount of$5,520,104 from 2018 onwards can be carried over indefinitely, subject to annual usage limits.",
    "valuationallowancedeferredtaxassetexplanationofchange": "Accordingly, the Company has provided a 100% valuation allowance on the deferred tax asset benefit related to theU.S. net operating loss and capital loss carry forwards to reduce the asset to zero.",
    "concentrationsriskpercentage1": 1,
    "supplementalunemploymentbenefitssalarycontinuation": 180000,
    "commercialsaleterm": 10,
    "licenseagreementexpire": 15,
    "royaltypaymentsdescription": "(i)",
    "otherdepreciationsandamortization": 92095,
    "paymentofsponsoredresearchamount": 838,
    "prepaidexpenses": 11034,
    "nonrefundablecashpayment": 500000,
    "netsalepercentage": 0.02,
    "licensorshare": 500,
    "aggregateofconvertedshares": 625000,
    "revenueterm": 15,
    "numberofvotingshares": 20000,
    "reversestocksplitvotedescription": "(i)the date that the Reverse Stock Split Vote is approved by Aikido’s stockholders and (ii) December 31, 2021, at the option of theholder, into such number of shares of Aikido’s common stock determined by dividing the Stated Value by the Conversion Price. “StatedValue” means $1,000. “Conversion Price” means $0.80, subject to adjustment.",
    "deferredrevenue": 1031250,
    "cashreceived": 500000,
    "securitiesreceived": 531250,
    "deferredrevenuerevenuerecognized1": 68750,
    "deferredrevenuecurrent": 3352,
    "deferredrevenuelongtermportion": 893750,
    "considerationfeepayablepercentage": 1.1,
    "upfrontlicensefees": 1900000,
    "firstcommercialsale": 10,
    "agreementshallexpire": 15,
    "recognizedrevenues": 2514,
    "otherlongtermdebt": 44134,
    "managementfeepayable": 433885,
    "companypaidcash": 5000,
    "paymentofuniversity": 5000,
    "entityregistrantname": "SILO PHARMA, INC",
    "documenttype": "10-K",
    "currentfiscalyearenddate": "December 31",
    "amendmentflag": "false",
    "entitycentralindexkey": 1514183,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "December 31, 2021",
    "documentfiscalyearfocus": 2021,
    "documentfiscalperiodfocus": "FY",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "true",
    "icfrauditorattestationflag": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "entityfilenumber": "000-54872",
    "entityincorporationstatecountrycode": "Delaware",
    "entitytaxidentificationnumber": "27-3046338",
    "entityaddressaddressline1": "560 Sylvan Avenue",
    "entityaddressaddressline2": "Suite 3160",
    "entityaddresscityortown": "Englewood Cliffs",
    "entityaddressstateorprovince": "New Jersey",
    "entityaddresspostalzipcode": 7632,
    "cityareacode": "(718)",
    "localphonenumber": "400-9031",
    "entityinteractivedatacurrent": "Yes",
    "auditorfirmid": 106,
    "auditorname": "Salberg &Company, P.A.",
    "auditorlocation": "Boca Raton, Florida"
  },
  {
    "date": "2020-12-30",
    "symbol": "SILO",
    "period": "FY",
    "cashandcashequivalentsatcarryingvalue": 1128389,
    "equitymethodinvestmentaggregatecost": 200,
    "notesandloansreceivablenetcurrent": 146500,
    "prepaidexpenseandotherassetscurrent": 241091,
    "inventorynet": 33484,
    "assetscurrent": 1426664,
    "assets": 1426664,
    "accountspayableandaccruedliabilitiescurrent": 127069,
    "notespayablecurrent": 14654,
    "liabilitiescurrent": 141723,
    "longtermnotesandloans": 4246,
    "liabilitiesnoncurrent": 4246,
    "liabilities": 145969,
    "commonstockvalue": 8514,
    "additionalpaidincapital": 7034502,
    "retainedearningsaccumulateddeficit": -5762321,
    "stockholdersequity": -5762321,
    "liabilitiesandstockholdersequity": 1426664,
    "temporaryequityparorstatedvaluepershare": 0.0001,
    "temporaryequitysharesdesignated": 1000000,
    "temporaryequityredemptionpricepershare": 100,
    "preferredstockparorstatedvaluepershare": 0.0001,
    "preferredstocksharesauthorized": 2000,
    "preferredstocksharesissued": 115,
    "preferredstocksharesoutstanding": 115,
    "preferredstockredemptionpricepershare": 1000,
    "commonstockparorstatedvaluepershare": 0.08,
    "commonstocksharesauthorized": 500000000,
    "commonstocksharesissued": 85141956,
    "commonstocksharesoutstanding": 85141956,
    "revenues": 40923,
    "costofgoodsandservicessold": 176126,
    "grossprofit": -135203,
    "sharebasedcompensation": 755993,
    "professionalfees": 1276562,
    "developmentcosts": 62550,
    "researchanddevelopmentexpense": 26250,
    "generalinsuranceexpense": 30191,
    "baddebtrecoveryexpense": 165376,
    "generalandadministrativeexpense": 120842,
    "operatingexpenses": 2437764,
    "operatingincomeloss": -2572967,
    "investmentincomenet": 11543,
    "otherincome": 3000,
    "interestexpensedebt": 269043,
    "interestexpenserelatedparty": 99,
    "foreigncurrencytransactiongainlossbeforetax": -2950,
    "gainslossesonextinguishmentofdebt": -197682,
    "unrealizedgainlossonequityinvestments": -9194,
    "nonoperatingincomeexpense": -464550,
    "netincomeloss": -3037517,
    "preferredstockdividendsincomestatementimpact": 69000,
    "netincomelossavailabletocommonstockholdersdiluted": -3106517,
    "earningspersharebasicanddiluted": -0.05,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 65954691,
    "sharesoutstanding": 85141956,
    "stockissuedduringperiodvaluenewissues": 2115733,
    "stockissuedduringperiodsharesnewissues": 37758116,
    "stockissuedforfutureservices": 686895,
    "commonstockissuedforfutureservicesshares": 8586184,
    "preferredsharesexchangedforcommonstock": -144,
    "preferredsharesexchangedforcommonstockshares": 1437500,
    "stockissuedduringperiodvalueemployeestockownershipplan": 610476,
    "stockissuedduringperiodsharesemployeestockownershipplan": 7630949,
    "commonstockissuedforexchangeofnotes": 528000,
    "commonstockissuedforexchangeofnotesshares": 4125000,
    "commonstockissuedforconversionofredeemableseriespreferredstock": 400000,
    "commonstockissuedforconversionofredeemableseriespreferredstockshares": 2000000,
    "deemeddividendonpreferredstockexchange": -69000,
    "profitloss": -3037517,
    "baddebtexpense": 165376,
    "allocatedstockbasedcompensation": 610476,
    "amortizationofprepaidstockbasedexpense": 578924,
    "otherdepreciationandamortization": 268125,
    "inventorywritedown": 137947,
    "unrealizedgainlossoninvestments": -9194,
    "lossfromdebtextinguishment": -197682,
    "increasedecreaseininventories": 15065,
    "increasedecreaseinprepaidexpensesother": 144663,
    "increasedecreaseinaccountspayableandaccruedliabilities": 72525,
    "netcashprovidedbyusedinoperatingactivities": -1156996,
    "proceedsfromcollectionofnotesreceivable": 39000,
    "netcashprovidedbyusedininvestingactivities": 39000,
    "proceedsfromrelatedpartydebt": 35000,
    "proceedsfromnotespayable": 18900,
    "proceedsfromrepaymentsofrelatedpartydebt": -35000,
    "proceedsfromissuanceofcommonstock": 610476,
    "netcashprovidedbyusedinfinancingactivities": 2134633,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseexcludingexchangerateeffect": 1016637,
    "interestpaidnet": 224,
    "commonstockissuedforprepaidservices": 686895,
    "commonstockissuedforexchangeofnotescash": 528000,
    "commonstockissuedforconversionofredeemableserieapreferredstock": 400000,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 300000,
    "inventoryrawmaterials": 1425,
    "inventoryfinishedgoods": 32059,
    "inventorynoncurrent": 33484,
    "notesreceivablegross": 250000,
    "collectionsonnotesreceivables": -30000,
    "financingreceivableallowanceforcreditlosses": 196500,
    "notesreceivablenet": 23500,
    "debtinstrumentfaceamount": 18900,
    "notrpayablelesscurrentportion": -14654,
    "notepayablelongtermportion": 4246,
    "futureminimumprincipalpaymentsduecurrent": 14654,
    "futureminimumprincipalpaymentsdueintwoyears": 4246,
    "totalprincipalpayments": 18900,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 300000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 0.0001,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresinperiod": 2225000,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsforfeituresinperiodweightedaverageexerciseprice": 0.2,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P3Y6M",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 300000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 0.0001,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": "P3Y6M",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableintrinsicvalue1": 127290,
    "incometaxreconciliationincometaxexpensebenefitatfederalstatutoryincometaxrate": -637879,
    "incometaxreconciliationstateandlocalincometaxes": -197439,
    "availableforsaleequitysecuritiesgrossunrealizedloss": 457798,
    "incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": 377520,
    "deferredtaxassetsoperatinglosscarryforwards": 868338,
    "deferredtaxassetscapitallosscarryforwards": 123932,
    "deferredtaxassetsgross": 992271,
    "deferredtaxassetsvaluationallowance": 992271,
    "payment": 43885,
    "paymentdescription": "Completion of data collection and delivery of final report",
    "umbpayment": 100000,
    "umbyeardescription": "Third calendar year following the First Commercial Sale",
    "milestonepayment": 1000000,
    "milestone": "Achievement of First Commercial Sale of Licensed Product",
    "cashfdicinsuredamount": 250000,
    "cashspicinsuredamount": 250000,
    "fdicindemnificationassetcashpaymentsreceived": 880000,
    "prepaidexpenseandotherassets": 241091,
    "inventorygross": 137947,
    "equityinvestmentscost": 200,
    "intangibleassetsamortizationperiod": "P1Y",
    "otherresearchanddevelopmentexpense": 26250,
    "allowancefordoubtfulaccountsreceivable": 174376,
    "notesreceivablepurchaseprice": 30000,
    "interestreceivable": 27876,
    "allowanceforloanandleaselossrecoveryofbaddebts": 9000,
    "debtconversionconvertedinstrumentwarrantsoroptionsissued1": 1650000,
    "classofwarrantorrightexercisepriceofwarrantsorrights1": 0.2,
    "additionalexpensesanddepositfees": 1250,
    "debtinstrumentconvertiblebeneficialconversionfeature": 253000,
    "amortizationofdebtdiscountpremium": 268125,
    "debtinstrumentincreaseaccruedinterest": 80,
    "interestexpense": 80,
    "preferredstockoutstandingdescription": "The Series A Preferred Stock has forced conversion rights where the Company may force the conversion of the Series A Preferred Stock if certain conditions are met. Additionally, the Company may elect to redeem some or all of the outstanding Series A Preferred Stock for the stated value (currently $100/share) provided that proper notice is provided to the holders and that a number of conditions have been met.",
    "debtinstrumentconvertibleconversionprice1": 0.3,
    "investorinvested": 100000,
    "investorinvestedamountpercentage": 0.5,
    "prepaidexpensecurrent": 107970,
    "extinguishmentofdebtamount": 198000,
    "netcapitallosscarryforward": 450663,
    "aggregateestimatednetoperatingloss": 3157594,
    "descriptionofincometaxdescription": "The 2017 carryforward will expire, if not utilized, through 2037. The 2020, 2019, and 2018 carryforwards shall be carried over indefinitely, subject to annual usage limits",
    "valuationallowancedeferredtaxassetexplanationofchange": "Accordingly, the Company has provided a 100% valuation allowance on the deferred tax asset benefit related to the U.S. net operating loss and capital loss carry forwards to reduce the asset to zero.",
    "concentrationriskpercentage1": 0.1,
    "amortizedoverperioddescription": "In December 2020, the Company paid the first payment which was recorded to prepaid expense and other current assets to be amortized over the four-year term.",
    "amortizationoffinancingcosts": 26250,
    "exceedpercentage": 1.1,
    "longtermdebtpercentagebearingvariableinterestrate": 0.05,
    "salestypeleaserevenue": 50000000,
    "participatingpolicypercentageofpremiumincome": 0.15,
    "licenseterm": "P10Y",
    "agreementexpireterm": "P15Y",
    "exercisabilitydescription": "A holder of Series C Convertible Preferred Stock may not convert any portion of the Series C Convertible Preferred Stock to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% (or, upon election by a holder prior to issuance, 9.99%) of the outstanding shares of common stock after conversion, which beneficial ownership limitation may be increased by the holder up to, but not exceeding, 9.99%.",
    "warrantexercisepricedecrease": 0.3,
    "conversionpercentage": 0.0999,
    "financingamountpercentage": 0.5,
    "subscriptionamountpercentage": 0.01,
    "aggregateofshares": 2850664,
    "equitymethodinvestmentownershippercentage": 0.1,
    "warrantexercisepriceincrease": 0.35,
    "entityregistrantname": "Silo Pharma, Inc.",
    "documenttype": "10-K",
    "currentfiscalyearenddate": "--12-31",
    "amendmentflag": "false",
    "entitycentralindexkey": 1514183,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "2020-12-31",
    "documentfiscalyearfocus": 2020,
    "documentfiscalperiodfocus": "FY",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "documenttransitionreport": "false",
    "entityfilenumber": "000-54872",
    "entityincorporationstatecountrycode": "DE",
    "entityinteractivedatacurrent": "Yes"
  },
  {
    "date": "2019-12-30",
    "symbol": "SILO",
    "period": "FY",
    "entityregistrantname": "Uppercut Brands, Inc.",
    "entitycentralindexkey": 1514183,
    "amendmentflag": "false",
    "currentfiscalyearenddate": "--12-31",
    "documenttype": "10-K",
    "documentperiodenddate": "2019-12-31",
    "documentfiscalperiodfocus": "FY",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "documentfiscalyearfocus": 2019,
    "entityfilercategory": "Non-accelerated Filer",
    "entitycurrentreportingstatus": "Yes",
    "entitysmallbusiness": "true",
    "entityshellcompany": "false",
    "entityemerginggrowthcompany": "false",
    "entityfilenumber": "000-54872",
    "entityinteractivedatacurrent": "Yes",
    "entityincorporationstatecountrycode": "DE",
    "cashandcashequivalentsatcarryingvalue": 111752,
    "equitymethodinvestmentaggregatecost": 9394,
    "notesandloansreceivablenetcurrent": 200000,
    "prepaidexpenseandotherassetscurrent": 16333,
    "inventorynet": 156366,
    "assetscurrent": 493845,
    "assets": 493845,
    "convertiblenotespayablecurrent": 61875,
    "accountspayableandaccruedliabilitiescurrent": 54862,
    "liabilitiescurrent": 116737,
    "temporaryequitycarryingamountattributabletoparent": 400000,
    "preferredstockvalue": 400000,
    "commonstockvalue": 2361,
    "additionalpaidincapital": 2630551,
    "retainedearningsaccumulateddeficit": -2655804,
    "stockholdersequity": -2655804,
    "liabilitiesandstockholdersequity": 493845,
    "temporaryequityparorstatedvaluepershare": 0.0001,
    "temporaryequitysharesdesignated": 1000000,
    "temporaryequitysharesissued": 4000,
    "temporaryequitysharesoutstanding": 4000,
    "temporaryequityredemptionpricepershare": 100,
    "preferredstockparorstatedvaluepershare": 0.0001,
    "preferredstocksharesauthorized": 2000,
    "preferredstocksharesissued": 115,
    "preferredstocksharesoutstanding": 115,
    "preferredstockredemptionpricepershare": 1000,
    "commonstockparorstatedvaluepershare": 0.0001,
    "commonstocksharesauthorized": 100000000,
    "commonstocksharesissued": 23604207,
    "commonstocksharesoutstanding": 23604207,
    "revenues": 40569,
    "costofgoodsandservicessold": 27387,
    "grossprofit": 13182,
    "sharebasedcompensation": 319587,
    "professionalfees": 431015,
    "developmentcosts": 63465,
    "generalinsuranceexpense": 26565,
    "baddebtrecoveryexpense": -13500,
    "generalandadministrativeexpense": 87013,
    "assetimpairmentcharges": 29440,
    "operatingexpenses": 943585,
    "operatingincomeloss": -930403,
    "investmentincomenet": 12196,
    "interestexpense": 62739,
    "interestexpenserelatedparty": 189,
    "realizedgainlossonequityinvestments": 138032,
    "unrealizedgainlossonequityinvestments": -170191,
    "nonoperatingincomeexpense": -82891,
    "netincomeloss": -1013294,
    "earningspersharebasicanddiluted": -0.04,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 23468522,
    "sharesoutstanding": 115,
    "seriesbpreferredstockissuedforcashnetofcosts": 110000,
    "seriesbpreferredstockissuedforcashnetofcostsshares": 115,
    "stockissuedduringperiodvalueissuedforservices": 34990,
    "stockissuedduringperiodsharesissuedforservices": 100000,
    "commonstockissuedforduediligencefee": 41991,
    "commonstockissuedforduediligencefeeshaes": 86667,
    "stockissueduringperiodaccretionofstockoptionsforservices": 142960,
    "debtconversionconvertedinstrumentamount1": 253000,
    "profitloss": -1013294,
    "allocatedstockbasedcompensation": 177960,
    "otherdepreciationandamortization": 61875,
    "realizedinvestmentgainslosses": 138032,
    "unrealizedgainlossoninvestments": -170191,
    "increasedecreaseininventories": 129393,
    "increasedecreaseinprepaidexpensesother": -17698,
    "increasedecreaseinaccountspayableandaccruedliabilities": 29231,
    "netcashprovidedbyusedinoperatingactivities": -794324,
    "paymentstoacquireequitymethodinvestments": 5197,
    "proceedsfromsaleofequitymethodinvestments": 191938,
    "netcashprovidedbyusedininvestingactivities": 186741,
    "proceedsfromissuanceofconvertiblepreferredstock": 110000,
    "proceedsfromconvertibledebt": 295000,
    "proceedsfromrelatedpartydebt": 25000,
    "repaymentofnotepayablerelatedparty": -25000,
    "repaymentofinsurancefinanceloan": 22344,
    "netcashprovidedbyusedinfinancingactivities": 382656,
    "cashandcashequivalentsperiodincreasedecrease": -224927,
    "commonstockissuedforacquisitionofintangibleassetsandprepaidexpenses": 300000,
    "commonstockissuedforduediligencefeeandrelatedincreaseindebtdiscount": 42000,
    "warrantsissuedinconnectionwithconvertibledebtandrelatedincreaseindebtdiscount": 253000,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 1650000,
    "cashfdicinsuredamount": 250000,
    "cashspicinsuredamount": 250000,
    "goodwillimpairmentloss": 87745,
    "businesscombinationrecognizedidentifiableassetsacquiredandliabilitiesassumedcurrentassetsprepaidexpenses": 17500,
    "businesscombinationrecognizedidentifiableassetsacquiredandliabilitiesassumedintangibles": 134735,
    "businesscombinationrecognizedidentifiableassetsacquiredandliabilitiesassumedassets": 152235,
    "businesscombinationconsiderationtransferred1": 152235,
    "trademarksacquiredattheirhistoricalcost": 29440,
    "descriptionofsocialmediainfluencer": "MAX is considered a social media influencer with over 600,000 Instagram followers and over 1.5 million YouTube subscribers.",
    "descriptionofroyalty": "Pursuant to the Brand Ambassador Agreement, the Company was to incur a minimum cash payment of $35,000 related to a minimum royalty payment of which $17,500 was paid prior to the Closing Date. The remaining $17,500 was due on January 27, 2019 and was not paid due to cancellation of the agreement.",
    "inventoryrawmaterials": 41231,
    "inventoryfinishedgoods": 115135,
    "notesreceivablegross": 250000,
    "financingreceivableallowanceforcreditlosses": 50000,
    "notesreceivablenet": 200000,
    "notesreceivableandrelatedinterestreceivableaggregatebalances": 277305,
    "notesreceivablepurchaseprice": 277305,
    "finitelivedintangibleassetusefullife": "P0Y",
    "saleleasebacktransactionhistoricalcost": 105295,
    "sharebasedgoodsandnonemployeeservicestransactionvaluationmethodexpectedterm1": "P5Y0M0D",
    "sharebasedgoodsandnonemployeeservicestransactionvaluationmethodexpectedvolatilityrate": 1.586,
    "sharebasedgoodsandnonemployeeservicestransactionvaluationmethodriskfreeinterestrate": 0.0166,
    "debtinstrumentannualprincipalpayment": 330000,
    "debtinstrumentunamortizeddiscount": 268125,
    "debtconversionconvertedinstrumentwarrantsoroptionsissued1": 1650000,
    "classofwarrantorrightexercisepriceofwarrantsorrights1": 0.2,
    "additionalexpensesanddepositfees": 1250,
    "debtinstrumentconvertiblebeneficialconversionfeature": 253000,
    "amortizationofdebtdiscountpremium": 61875,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 300000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 2225000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresinperiod": 100000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 300000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 0.0001,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 0.2,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsforfeituresinperiodweightedaverageexerciseprice": 0.0001,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageexerciseprice": 0.0001,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P4Y9M18D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": "P4Y9M18D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingintrinsicvalue": 104970,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableintrinsicvalue1": 104970,
    "allocatedsharebasedcompensationexpense": 35000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.0237,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P5Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 1.586,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingfairvalue": 142960,
    "sharesissued": 100000,
    "preferredstockstatedvalue": 1000,
    "preferredstockoutstandingdescription": "The Series A Preferred Stock has forced conversion rights where the Company may force the conversion of the Series A Preferred Stock if certain conditions are met. Additionally, the Company may elect to redeem some or all of the outstanding Series A Preferred Stock for the Stated Value (currently $100/share) provided that proper notice is provided to the holders and that a number of conditions (the “Equity Conditions”) have been met.",
    "debtinstrumentconvertibleconversionprice1": 0.2,
    "incometaxreconciliationincometaxexpensebenefitatfederalstatutoryincometaxrate": -212792,
    "incometaxreconciliationstateandlocalincometaxes": -65864,
    "availableforsaleequitysecuritiesgrossunrealizedloss": 103132,
    "incometaxreconciliationtaxcredits": 59266,
    "incometaxreconciliationchangeindeferredtaxassetsvaluationallowance": 116258,
    "deferredtaxassetsoperatinglosscarryforwards": 490819,
    "deferredtaxassetscapitallosscarryforwards": 123932,
    "deferredtaxassetsgross": 614751,
    "deferredtaxassetsvaluationallowance": 614751,
    "netcapitallosscarryforward": 450663,
    "aggregateestimatednetoperatingloss": 1785000,
    "valuationallowancedeferredtaxassetexplanationofchange": "Accordingly, the Company has provided a 100% valuation allowance on the deferred tax asset benefit related to the U.S. net operating loss and capital loss carry forwards to reduce the asset to zero.",
    "descriptionofincometaxdescription": "The 2017 carryforward will expire, if not utilized, through 2037. The 2019 and 2018 carryforwards shall be carried over indefinitely, subject to annual usage limits.",
    "concentrationriskpercentage1": 0.986
  }
]